A case of primary progressive multiple sclerosis with improvement in cognitive impairment by anti-CD20 monoclonal antibody therapy
The patient was a 44-year-old man who developed cognitive impairment beginning at the age of 35 years that gradually worsened. The cognitive impairment led to a difficult social life, and he retired from his company. After hospitalization and workup, he was diagnosed with primary progressive multiple sclerosis (PPMS) that presented only with cognitive impairment for 10 years. Since he had multiple predictive factors for poor prognosis, anti-CD20 monoclonal antibody therapy was implemented. Cognitive impairment and cerebral blood flow SPECT findings improved, and he returned to a social life 3 months later. Anti-CD20 monoclonal antibody therapy was effective in improving cognitive impairment in a case of an advanced stage of PPMS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Rinsho shinkeigaku = Clinical neurology - 63(2023), 3 vom: 29. März, Seite 152-158 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Onoue, Hiroyuki [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.03.2023 Date Revised 31.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5692/clinicalneurol.cn-001779 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353492116 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353492116 | ||
| 003 | DE-627 | ||
| 005 | 20231226060125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.5692/clinicalneurol.cn-001779 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353492116 | ||
| 035 | |a (NLM)36843088 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Onoue, Hiroyuki |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A case of primary progressive multiple sclerosis with improvement in cognitive impairment by anti-CD20 monoclonal antibody therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2023 | ||
| 500 | |a Date Revised 31.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The patient was a 44-year-old man who developed cognitive impairment beginning at the age of 35 years that gradually worsened. The cognitive impairment led to a difficult social life, and he retired from his company. After hospitalization and workup, he was diagnosed with primary progressive multiple sclerosis (PPMS) that presented only with cognitive impairment for 10 years. Since he had multiple predictive factors for poor prognosis, anti-CD20 monoclonal antibody therapy was implemented. Cognitive impairment and cerebral blood flow SPECT findings improved, and he returned to a social life 3 months later. Anti-CD20 monoclonal antibody therapy was effective in improving cognitive impairment in a case of an advanced stage of PPMS | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-CD20 monoclonal antibody | |
| 650 | 4 | |a cognitive impairment | |
| 650 | 4 | |a poor prognosis predictors | |
| 650 | 4 | |a primary progressive multiple sclerosis | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Kato, Yuta |e verfasserin |4 aut | |
| 700 | 1 | |a Ishido, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Akaiwa, Yasuhisa |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamoto, Tomoyuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho shinkeigaku = Clinical neurology |d 1972 |g 63(2023), 3 vom: 29. März, Seite 152-158 |w (DE-627)NLM000226874 |x 1882-0654 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2023 |g number:3 |g day:29 |g month:03 |g pages:152-158 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5692/clinicalneurol.cn-001779 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2023 |e 3 |b 29 |c 03 |h 152-158 | ||